Document Detail


A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis.
MedLine Citation:
PMID:  20721949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The synthesis and utility of a multimodal theranostic nanoagent based upon magnetofluorescent nanoparticles for the treatment of inflammatory atherosclerosis is described. These particles are modified with near-infrared fluorophores and light-activated therapeutic moieties, which allow for the optical determination of agent localization and phototoxic activation at spectrally distinct wavelengths. The resulting agent is readily taken up by murine macrophages in vitro and is highly phototoxic, with an LD(50) of 430 pM. Intravenous administration results in the localization of the nanoagent within macrophage-rich atherosclerotic lesions that can be imaged by intravital fluorescence microscopy. Irradiation of the atheroma with 650 nm light activates the therapeutic component and results in eradication of inflammatory macrophages, which may induce lesion stabilization. Importantly, these agents display limited skin photosensitivity, are highly efficacious, and provide an integrated imaging and therapeutic nanoplatform for atherosclerosis.
Authors:
Jason R McCarthy; Ethan Korngold; Ralph Weissleder; Farouc A Jaffer
Related Documents :
17002259 - Antibodies against oxidized low-density lipoprotein for the treatment of vulnerable pla...
13679329 - Giant-cell arteritis and polymyalgia rheumatica.
19414539 - Mechanisms and consequences of efferocytosis in advanced atherosclerosis.
18666849 - Influence of cd4+/cd25+ regulatory t cells on atherogenesis in patients with end-stage ...
18497309 - Lentiviral transduction of apoai into hematopoietic progenitor cells and macrophages: a...
17854929 - Myocardial infarction after meningococcal infection: a potential inflammatory link or a...
17456759 - Induction of apoptosis by crambene protects mice against acute pancreatitis via anti-in...
12719479 - Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2.
21282039 - Il-2: a two-faced master regulator of autoimmunity.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Small (Weinheim an der Bergstrasse, Germany)     Volume:  6     ISSN:  1613-6829     ISO Abbreviation:  Small     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-20     Completed Date:  2011-02-02     Revised Date:  2012-04-26    
Medline Journal Info:
Nlm Unique ID:  101235338     Medline TA:  Small     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  2041-9     Citation Subset:  IM    
Affiliation:
Harvard Medical School, Boston, MA 02114, USA. jason_mccarthy@hms.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apolipoproteins E / genetics
Atherosclerosis / complications,  pathology,  therapy*
Cell Separation / methods
Cells, Cultured
Drug Delivery Systems / methods*
Female
Inflammation / complications,  pathology,  therapy*
Light
Macrophages / drug effects*,  pathology
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Models, Biological
Nanostructures / administration & dosage,  radiation effects,  therapeutic use*
Phototherapy / methods*
Grant Support
ID/Acronym/Agency:
R21 HL093607-01A1/HL/NHLBI NIH HHS; R21HL093607/HL/NHLBI NIH HHS; U01-HL080731/HL/NHLBI NIH HHS; //Howard Hughes Medical Institute
Chemical
Reg. No./Substance:
0/Apolipoproteins E
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vertical nanowire architectures: statistical processing of porous templates towards discrete nanocha...
Next Document:  Photocatalytic activity of protein-conjugated CdS nanoparticles.